Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment

Samsung Biologics
Press:?cair.kim@samsung.com Vir Biotechnology, Inc. Investors
Neera Ravindran, MD
Head of Investor Relations & Strategic Communications
nravindran@vir.bio
+1-415-506-5256 Media
Lindy Devereux
Scient PR
lindy@scientpr.com
+1-646-515-5730 SOURCE Samsung Biologics; Vir Biotechnology